CRISPR Financial Statements From 2010 to 2022

CRSP -  USA Stock  

USD 56.34  1.63  2.98%

CRISPR Therapeutics financial statements provide useful quarterly and yearly information to potential CRISPR Therapeutics AG investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on CRISPR Therapeutics financial statements helps investors assess CRISPR Therapeutics' valuation, profitability, and current liquidity needs.
There are currently eighty-one fundamental signals for CRISPR Therapeutics AG that can be evaluated and compared over time across rivals. Make sure you validate CRISPR Therapeutics' prevailing fundamentals against the trend between 2010 and 2022 to make sure the company can sustain itself for few more years.
CRISPR Therapeutics Invested Capital Average is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Invested Capital Average of 1.48 Billion. As of 24th of May 2022, Tangible Asset Value is likely to grow to about 3 B, while Enterprise Value is likely to drop about 4.5 B.
  
Refresh
Check CRISPR Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CRISPR main balance sheet or income statement drivers, such as Consolidated Income of 407.5 M, Earning Before Interest and Taxes EBIT of 409.5 M or Gross Profit of 987.2 M, as well as many exotic indicators such as Asset Turnover of 0.38, Book Value per Share of 34.09 or Current Ratio of 19.3. CRISPR financial statements analysis is a perfect complement when working with CRISPR Therapeutics Valuation or Volatility modules. It can also supplement various CRISPR Therapeutics Technical models. Continue to the analysis of CRISPR Therapeutics Correlation against competitors.

CRISPR Therapeutics Revenues

987.2 Million

Share

CRISPR Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total AssetsB2.8 B760.6 M
Increasing
Slightly volatile
Cash and Equivalents802.5 M939.9 M389.2 M
Increasing
Slightly volatile
Investments1.3 B1.5 B656.4 M
Increasing
Slightly volatile
Investments Current1.3 B1.5 B656.4 M
Increasing
Slightly volatile
Deferred Revenue13.7 M13.3 M53.6 M
Decreasing
Slightly volatile
Property Plant and Equipment Net336.7 M312 M67.8 M
Increasing
Slightly volatile
Trade and Non Trade Receivables313 K305 K674.3 K
Decreasing
Very volatile
Trade and Non Trade Payables16 M14.8 M4.6 M
Increasing
Slightly volatile
Goodwill and Intangible Assets128.3 K125 K361.5 K
Decreasing
Slightly volatile
Total Liabilities380.2 M352.4 M111.6 M
Increasing
Slightly volatile
Shareholders Equity2.6 B2.4 B641.6 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income(5.2 M)(5.1 M)(798.6 K)
Decreasing
Slightly volatile
Current Assets2.6 B2.4 B686.7 M
Increasing
Slightly volatile
Assets Non Current360.8 M334.4 M74 M
Increasing
Slightly volatile
Current Liabilities129.3 M119.9 M37.4 M
Increasing
Slightly volatile
Liabilities Non Current250.9 M232.5 M74.3 M
Increasing
Slightly volatile
Tax Liabilities743.1 K724 KM
Increasing
Slightly volatile
Total Debt242.8 M225 M74.6 M
Increasing
Slightly volatile
Debt Current12.6 M12.2 M9.3 M
Increasing
Slightly volatile
Debt Non Current229.7 M212.9 M69.1 M
Increasing
Slightly volatile
Shareholders Equity USD2.6 B2.4 B641.6 M
Increasing
Slightly volatile
Cash and Equivalents USD802.5 M939.9 M389.2 M
Increasing
Slightly volatile
Total Debt USD242.8 M225 M74.6 M
Increasing
Slightly volatile

CRISPR Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues987.2 M915 M172.6 M
Increasing
Slightly volatile
Selling General and Administrative Expense82.2 M102.8 M37.8 M
Increasing
Slightly volatile
Research and Development Expense473.3 M438.6 M123.4 M
Increasing
Slightly volatile
Operating Expenses584.2 M541.4 M163.4 M
Increasing
Slightly volatile
Interest Expense10 M9.3 M4.6 M
Increasing
Slightly volatile
Income Tax ExpenseM1.9 M586.4 K
Increasing
Slightly volatile
Consolidated Income407.5 M377.7 M14.4 M
Increasing
Slightly volatile
Net Income407.5 M377.7 M14.6 M
Increasing
Slightly volatile
Preferred Dividends Income Statement Impact666.6 K670.5 K733.2 K
Decreasing
Slightly volatile
Net Income Common Stock407.5 M377.7 M14.3 M
Increasing
Slightly volatile
Weighted Average Shares62.1 M75.9 M29.3 M
Increasing
Slightly volatile
Weighted Average Shares Diluted64.9 M80.4 M30.1 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT409.5 M379.5 M15.8 M
Increasing
Slightly volatile
Revenues USD987.2 M915 M172.6 M
Increasing
Slightly volatile
Net Income Common Stock USD407.5 M377.7 M14.3 M
Increasing
Slightly volatile
Earning Before Interest and Taxes USD409.5 M379.5 M15.8 M
Increasing
Slightly volatile
Gross Profit987.2 M915 M172.6 M
Increasing
Slightly volatile
Operating Income403 M373.5 M9.1 M
Increasing
Stable

CRISPR Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Business Acquisitions and Disposals7.2 M7.2 M7.9 M
Decreasing
Slightly volatile
Net Cash Flow from Financing298.6 M250.9 M201.6 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities 32 M31.5 M36 M
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares284.5 M250.9 M183.9 M
Increasing
Slightly volatile
Net Cash Flow from Investing(1.1 B)(1 B)(201.9 M)
Decreasing
Slightly volatile
Net Cash Flow from Operations581.5 M539 M58.1 M
Increasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (11.3 K)(11 K)84.3 K
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(252 M)(245.5 M)53 M
Decreasing
Very volatile
Share Based Compensation110.5 M102.4 M30.4 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion19.4 M18 M4.5 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share5.364.970.3095
Decreasing
Very volatile
Earnings per Diluted Share5.074.70.2618
Decreasing
Very volatile
Earnings per Basic Share USD5.364.970.3095
Decreasing
Very volatile
Return on Average Equity0.170.1620.5807
Decreasing
Slightly volatile
Return on Average Assets0.160.145(0.19)
Increasing
Slightly volatile
Return on Invested Capital0.280.256(3.4336)
Decreasing
Very volatile
Gross Margin0.890.90.9842
Decreasing
Slightly volatile
Profit Margin0.510.47(6.4823)
Decreasing
Very volatile
EBITDA Margin0.540.5(5.3792)
Decreasing
Very volatile
Return on Sales0.450.415(88.9839)
Increasing
Very volatile
Asset Turnover0.380.3510.1025
Increasing
Slightly volatile
Enterprise Value over EBITDA13.512.519(21.1558)
Increasing
Slightly volatile
Enterprise Value over EBIT14.0313.0(19.2287)
Increasing
Slightly volatile
Price to Earnings Ratio16.4515.247(3.4465)
Increasing
Slightly volatile
Sales per Share13.012.0472.4756
Increasing
Slightly volatile
Price to Sales Ratio6.466.291.1 K
Increasing
Stable
Price to Book Value3.012.4173.7436
Increasing
Stable
Debt to Equity Ratio0.160.147(0.3167)
Increasing
Stable
Current Ratio19.320.16610.8581
Increasing
Slightly volatile
Free Cash Flow per Share6.56.0210.4471
Increasing
Stable
Book Value per Share34.0931.5939.5597
Increasing
Slightly volatile
Tangible Assets Book Value per Share30.6936.23214.7917
Increasing
Slightly volatile

CRISPR Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax409.5 M379.5 M15.2 M
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA428.9 M397.5 M20.4 M
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD428.9 M397.5 M20.4 M
Increasing
Slightly volatile
Market Capitalization5.3 B5.8 B2.6 B
Increasing
Slightly volatile
Enterprise Value4.5 BB2.1 B
Increasing
Slightly volatile
Invested Capital2.1 B1.9 B365.1 M
Increasing
Slightly volatile
Average Equity2.5 B2.3 B549.6 M
Increasing
Slightly volatile
Average Assets2.8 B2.6 B686.3 M
Increasing
Slightly volatile
Invested Capital Average1.6 B1.5 B275.2 M
Increasing
Slightly volatile
Tangible Asset ValueB2.8 B760.3 M
Increasing
Slightly volatile
Free Cash Flow493.4 M457.3 M42 M
Increasing
Slightly volatile
Working Capital2.5 B2.3 B649.3 M
Increasing
Slightly volatile

CRISPR Fundamental Market Drivers

Short Percent Of Float15.19%
Forward Price Earnings-7.54
Shares Short Prior Month10.05M
Average Daily Volume Last 10 Day1.75M
Average Daily Volume In Three Month1.45M
Date Short Interest29th of April 2022
Fifty Day Average58.48
Two Hundred Day Average81.06

CRISPR Upcoming Events

Upcoming Quarterly Report15th of February 2022
Next Financial Report26th of April 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End15th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About CRISPR Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include CRISPR Therapeutics income statement, its balance sheet, and the statement of cash flows. CRISPR Therapeutics investors use historical funamental indicators, such as CRISPR Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although CRISPR Therapeutics investors may use each financial statement separately, they are all related. The changes in CRISPR Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CRISPR Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on CRISPR Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in CRISPR Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue13.3 M13.7 M
Revenues915 M987.2 M
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

CRISPR Therapeutics Investors Sentiment

The influence of CRISPR Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in CRISPR. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

CRISPR Therapeutics Implied Volatility

    
  111.13  
CRISPR Therapeutics' implied volatility exposes the market's sentiment of CRISPR Therapeutics AG stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if CRISPR Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that CRISPR Therapeutics stock will not fluctuate a lot when CRISPR Therapeutics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CRISPR Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CRISPR Therapeutics' short interest history, or implied volatility extrapolated from CRISPR Therapeutics options trading.

Current Sentiment - CRSP

CRISPR Therapeutics Investor Sentiment

Most of Macroaxis users are currently bullish on CRISPR Therapeutics AG. What is your opinion about investing in CRISPR Therapeutics AG? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

CRISPR Therapeutics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of CRISPR Therapeutics Correlation against competitors. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.